Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Files China NDA for Hunter Syndrome Drug

publication date: Jul 29, 2019

CANbridge Pharma of Beijing filed an NDA in China for a rare disease treatment that targets Hunter Syndrome. Hunterase (idursulfase beta) is a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy. CANbridge in-licensed China rights to the candidate from GC Pharma of Korea in January of this year. The drug is already available in ten countries. Hunter Syndrome is a rare and often fatal genetic disease that occurs more frequently in Asia than in the West. More details....

Stock Symbol: (KRX: 006280)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here